Original data (with adjusted standard errors for multi-arm studies):

              treat1     treat2      TE   seTE seTE.adj.f seTE.adj.r narms multiarm
2            placebo   zolpidem  0.2385 0.1315     0.1315     0.1915     2         
3   BZD-intermediate  BZD-short -0.3793 0.1526     0.1526     0.2066     2         
4           BZD-long  BZD-short  0.0872 0.2562     0.2562     0.2916     2         
5            placebo   zolpidem  0.2857 0.1444     0.2310     0.2670     3        *
5           zaleplon   zolpidem  0.1905 0.1153     0.1278     0.2124     3        *
5            placebo   zaleplon  0.0952 0.1193     0.1337     0.2174     3        *
12       eszopiclone    placebo -0.6599 0.4718     0.4718     0.4919     2         
15  BZD-intermediate    placebo -0.5484 0.1703     0.1958     0.2598     3        *
15          BZD-long    placebo -0.8186 0.1983     0.2861     0.3234     3        *
15  BZD-intermediate   BZD-long  0.2701 0.1687     0.1932     0.2575     3        *
20          BZD-long  zopiclone -0.0416 0.1981     0.1981     0.2421     2         
21         BZD-short    placebo -0.9088 0.2512     0.2512     0.2872     2         
25           placebo   zaleplon  0.0000 0.1137     0.1313     0.2151     3        *
25           placebo   zolpidem  0.0000 0.1310     0.1837     0.2453     3        *
25          zaleplon   zolpidem  0.0000 0.1146     0.1330     0.2164     3        *
32           placebo   zaleplon  0.0545 0.1238     0.1420     0.2211     3        *
32          zaleplon   zolpidem -0.0234 0.1295     0.1520     0.2291     3        *
32           placebo   zolpidem  0.0312 0.1451     0.2024     0.2593     3        *
39           placebo   zolpidem  0.6358 0.1267     0.1267     0.1882     2         
43           placebo   zaleplon  0.3939 0.1074     0.1074     0.1758     2         
44  BZD-intermediate    placebo -0.5534 0.2631     0.2631     0.2977     2         
45           placebo suvorexant -0.0000 0.0827     0.0827     0.1619     2         
46           placebo suvorexant -0.0000 0.0862     0.0862     0.1637     2         
47           placebo   zolpidem  0.3870 0.4410     0.4410     0.4624     2         
58       eszopiclone    placebo -0.3946 0.0830     0.0830     0.1621     2         
59           placebo   zolpidem  0.0467 0.0661     0.0661     0.1541     2         
62           placebo   zolpidem  0.2257 0.2210     0.2210     0.2612     2         
68  BZD-intermediate  zopiclone  0.4180 0.1635     0.1635     0.2147     2         
71          BZD-long  BZD-short  1.0086 0.6130     0.6130     0.6286     2         
72          BZD-long  BZD-short  0.3846 0.4108     0.5045     0.5325     3        *
72         BZD-short    placebo -0.0962 0.4084     0.4987     0.5271     3        *
72          BZD-long    placebo  0.2885 0.4097     0.5018     0.5300     3        *
74          BZD-long  BZD-short  0.2666 0.3176     0.3176     0.3468     2         
75           placebo  ramelteon -0.1623 0.0943     0.0943     0.1682     2         
77       eszopiclone    placebo -0.2217 0.1257     0.1257     0.1876     2         
81           placebo   zolpidem -1.3914 0.6434     0.6434     0.6583     2         
103 BZD-intermediate  zopiclone  0.8636 0.4185     0.4185     0.4411     2         
105          placebo   zolpidem  0.2694 0.1424     0.1424     0.1992     2         
114          placebo   zolpidem  0.2704 0.1425     0.1425     0.1992     2         
119          placebo   zolpidem -0.1905 0.2989     0.2989     0.3297     2         
120      eszopiclone    placebo -0.1539 0.1385     0.1385     0.1964     2         
121          placebo  trazodone  0.1312 0.2606     0.2606     0.2955     2         
123      eszopiclone    placebo -0.5516 0.2358     0.2358     0.2738     2         
127          placebo  ramelteon  0.0455 0.0647     0.0647     0.1535     2         
132          placebo  trazodone  0.2841 0.1469     0.1793     0.2475     3        *
132        trazodone   zolpidem -0.0710 0.1487     0.1840     0.2508     3        *
132          placebo   zolpidem  0.2131 0.1462     0.1778     0.2464     3        *
135          placebo   zolpidem  0.1544 0.1733     0.1733     0.2223     2         
137          placebo   zolpidem -0.0854 0.1398     0.1398     0.1973     2         
144      eszopiclone    placebo -0.1288 0.1221     0.1221     0.1852     2         
149 BZD-intermediate  trazodone -0.1431 0.1834     0.1834     0.2302     2         
156          placebo   zaleplon  0.0757 0.1092     0.1092     0.1769     2         
159     daridorexant    placebo  0.0502 0.0696     0.0696     0.1556     2         
160     daridorexant    placebo  0.0432 0.0805     0.0805     0.1608     2         

Number of treatment arms (by study):
    narms
2       2
3       2
4       2
5       3
12      2
15      3
20      2
21      2
25      3
32      3
39      2
43      2
44      2
45      2
46      2
47      2
58      2
59      2
62      2
68      2
71      2
72      3
74      2
75      2
77      2
81      2
103     2
105     2
114     2
119     2
120     2
121     2
123     2
127     2
132     3
135     2
137     2
144     2
149     2
156     2
159     2
160     2

Results (fixed effects model):

              treat1     treat2     SMD             95%-CI     Q leverage
2            placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.31     0.07
3   BZD-intermediate  BZD-short -0.0181 [-0.2421;  0.2058]  5.60     0.56
4           BZD-long  BZD-short -0.0939 [-0.3425;  0.1548]  0.50     0.25
5            placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.27        .
5           zaleplon   zolpidem  0.0351 [-0.0646;  0.1348]  1.48        .
5            placebo   zaleplon  0.1303 [ 0.0394;  0.2212]  0.07        .
12       eszopiclone    placebo -0.2881 [-0.3929; -0.1834]  0.62     0.01
15  BZD-intermediate    placebo -0.5429 [-0.7529; -0.3329]  0.00        .
15          BZD-long    placebo -0.6186 [-0.8841; -0.3531]  0.49        .
15  BZD-intermediate   BZD-long  0.0757 [-0.1513;  0.3028]  1.01        .
20          BZD-long  zopiclone  0.2368 [-0.0395;  0.5131]  1.98     0.51
21         BZD-short    placebo -0.5248 [-0.7841; -0.2654]  2.34     0.28
25           placebo   zaleplon  0.1303 [ 0.0394;  0.2212]  0.98        .
25           placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.81        .
25          zaleplon   zolpidem  0.0351 [-0.0646;  0.1348]  0.07        .
32           placebo   zaleplon  0.1303 [ 0.0394;  0.2212]  0.28        .
32          zaleplon   zolpidem  0.0351 [-0.0646;  0.1348]  0.15        .
32           placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.44        .
39           placebo   zolpidem  0.1654 [ 0.0963;  0.2345] 13.79     0.08
43           placebo   zaleplon  0.1303 [ 0.0394;  0.2212]  6.02     0.19
44  BZD-intermediate    placebo -0.5429 [-0.7529; -0.3329]  0.00     0.17
45           placebo suvorexant -0.0000 [-0.1169;  0.1169]  0.00     0.52
46           placebo suvorexant -0.0000 [-0.1169;  0.1169]  0.00     0.48
47           placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.25     0.01
58       eszopiclone    placebo -0.2881 [-0.3929; -0.1834]  1.65     0.41
59           placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  3.23     0.28
62           placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.07     0.03
68  BZD-intermediate  zopiclone  0.3125 [ 0.0613;  0.5637]  0.42     0.61
71          BZD-long  BZD-short -0.0939 [-0.3425;  0.1548]  3.23     0.04
72          BZD-long  BZD-short -0.0939 [-0.3425;  0.1548]  0.90        .
72         BZD-short    placebo -0.5248 [-0.7841; -0.2654]  0.74        .
72          BZD-long    placebo -0.6186 [-0.8841; -0.3531]  3.27        .
74          BZD-long  BZD-short -0.0939 [-0.3425;  0.1548]  1.29     0.16
75           placebo  ramelteon -0.0210 [-0.1256;  0.0836]  2.24     0.32
77       eszopiclone    placebo -0.2881 [-0.3929; -0.1834]  0.28     0.18
81           placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  5.85     0.00
103 BZD-intermediate  zopiclone  0.3125 [ 0.0613;  0.5637]  1.73     0.09
105          placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.53     0.06
114          placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.54     0.06
119          placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  1.42     0.01
120      eszopiclone    placebo -0.2881 [-0.3929; -0.1834]  0.94     0.15
121          placebo  trazodone  0.2820 [ 0.0807;  0.4833]  0.33     0.16
123      eszopiclone    placebo -0.2881 [-0.3929; -0.1834]  1.25     0.05
127          placebo  ramelteon -0.0210 [-0.1256;  0.0836]  1.06     0.68
132          placebo  trazodone  0.2820 [ 0.0807;  0.4833]  0.00        .
132        trazodone   zolpidem -0.1166 [-0.3224;  0.0892]  0.06        .
132          placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.07        .
135          placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  0.00     0.04
137          placebo   zolpidem  0.1654 [ 0.0963;  0.2345]  3.22     0.06
144      eszopiclone    placebo -0.2881 [-0.3929; -0.1834]  1.70     0.19
149 BZD-intermediate  trazodone -0.2609 [-0.5046; -0.0171]  0.41     0.46
156          placebo   zaleplon  0.1303 [ 0.0394;  0.2212]  0.25     0.18
159     daridorexant    placebo  0.0472 [-0.0560;  0.1504]  0.00     0.57
160     daridorexant    placebo  0.0472 [-0.0560;  0.1504]  0.00     0.43

Results (random effects model):

              treat1     treat2     SMD             95%-CI
2            placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
3   BZD-intermediate  BZD-short  0.0418 [-0.2411;  0.3247]
4           BZD-long  BZD-short -0.0130 [-0.3034;  0.2774]
5            placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
5           zaleplon   zolpidem  0.0423 [-0.1168;  0.2013]
5            placebo   zaleplon  0.1345 [-0.0119;  0.2809]
12       eszopiclone    placebo -0.2816 [-0.4478; -0.1154]
15  BZD-intermediate    placebo -0.5297 [-0.7886; -0.2709]
15          BZD-long    placebo -0.5845 [-0.8982; -0.2708]
15  BZD-intermediate   BZD-long  0.0548 [-0.2268;  0.3364]
20          BZD-long  zopiclone  0.2581 [-0.0842;  0.6004]
21         BZD-short    placebo -0.5715 [-0.8807; -0.2623]
25           placebo   zaleplon  0.1345 [-0.0119;  0.2809]
25           placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
25          zaleplon   zolpidem  0.0423 [-0.1168;  0.2013]
32           placebo   zaleplon  0.1345 [-0.0119;  0.2809]
32          zaleplon   zolpidem  0.0423 [-0.1168;  0.2013]
32           placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
39           placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
43           placebo   zaleplon  0.1345 [-0.0119;  0.2809]
44  BZD-intermediate    placebo -0.5297 [-0.7886; -0.2709]
45           placebo suvorexant  0.0000 [-0.2257;  0.2257]
46           placebo suvorexant  0.0000 [-0.2257;  0.2257]
47           placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
58       eszopiclone    placebo -0.2816 [-0.4478; -0.1154]
59           placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
62           placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
68  BZD-intermediate  zopiclone  0.3128 [-0.0026;  0.6283]
71          BZD-long  BZD-short -0.0130 [-0.3034;  0.2774]
72          BZD-long  BZD-short -0.0130 [-0.3034;  0.2774]
72         BZD-short    placebo -0.5715 [-0.8807; -0.2623]
72          BZD-long    placebo -0.5845 [-0.8982; -0.2708]
74          BZD-long  BZD-short -0.0130 [-0.3034;  0.2774]
75           placebo  ramelteon -0.0490 [-0.2712;  0.1732]
77       eszopiclone    placebo -0.2816 [-0.4478; -0.1154]
81           placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
103 BZD-intermediate  zopiclone  0.3128 [-0.0026;  0.6283]
105          placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
114          placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
119          placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
120      eszopiclone    placebo -0.2816 [-0.4478; -0.1154]
121          placebo  trazodone  0.2778 [ 0.0163;  0.5393]
123      eszopiclone    placebo -0.2816 [-0.4478; -0.1154]
127          placebo  ramelteon -0.0490 [-0.2712;  0.1732]
132          placebo  trazodone  0.2778 [ 0.0163;  0.5393]
132        trazodone   zolpidem -0.1010 [-0.3719;  0.1699]
132          placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
135          placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
137          placebo   zolpidem  0.1768 [ 0.0705;  0.2831]
144      eszopiclone    placebo -0.2816 [-0.4478; -0.1154]
149 BZD-intermediate  trazodone -0.2519 [-0.5593;  0.0555]
156          placebo   zaleplon  0.1345 [-0.0119;  0.2809]
159     daridorexant    placebo  0.0468 [-0.1724;  0.2660]
160     daridorexant    placebo  0.0468 [-0.1724;  0.2660]

Number of studies: k = 42
Number of pairwise comparisons: m = 54
Number of observations: o = 11751
Number of treatments: n = 12
Number of designs: d = 18

Fixed effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z  p-value
BZD-intermediate -0.5429 [-0.7529; -0.3329] -5.07 < 0.0001
BZD-long         -0.6186 [-0.8841; -0.3531] -4.57 < 0.0001
BZD-short        -0.5248 [-0.7841; -0.2654] -3.97 < 0.0001
daridorexant      0.0472 [-0.0560;  0.1504]  0.90   0.3701
eszopiclone      -0.2881 [-0.3929; -0.1834] -5.39 < 0.0001
placebo                .                  .     .        .
ramelteon         0.0210 [-0.0836;  0.1256]  0.39   0.6938
suvorexant        0.0000 [-0.1169;  0.1169]  0.00   1.0000
trazodone        -0.2820 [-0.4833; -0.0807] -2.75   0.0060
zaleplon         -0.1303 [-0.2212; -0.0394] -2.81   0.0050
zolpidem         -0.1654 [-0.2345; -0.0963] -4.69 < 0.0001
zopiclone        -0.8554 [-1.1682; -0.5426] -5.36 < 0.0001

Random effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z  p-value             95%-PI
BZD-intermediate -0.5297 [-0.7886; -0.2709] -4.01 < 0.0001 [-0.9189; -0.1405]
BZD-long         -0.5845 [-0.8982; -0.2708] -3.65   0.0003 [-1.0147; -0.1543]
BZD-short        -0.5715 [-0.8807; -0.2623] -3.62   0.0003 [-0.9983; -0.1448]
daridorexant      0.0468 [-0.1724;  0.2660]  0.42   0.6757 [-0.3154;  0.4090]
eszopiclone      -0.2816 [-0.4478; -0.1154] -3.32   0.0009 [-0.6122;  0.0490]
placebo                .                  .     .        .                  .
ramelteon         0.0490 [-0.1732;  0.2712]  0.43   0.6657 [-0.3152;  0.4131]
suvorexant       -0.0000 [-0.2257;  0.2257] -0.00   1.0000 [-0.3664;  0.3664]
trazodone        -0.2778 [-0.5393; -0.0163] -2.08   0.0373 [-0.6689;  0.1133]
zaleplon         -0.1345 [-0.2809;  0.0119] -1.80   0.0717 [-0.4550;  0.1859]
zolpidem         -0.1768 [-0.2831; -0.0705] -3.26   0.0011 [-0.4798;  0.1262]
zopiclone        -0.8426 [-1.2271; -0.4580] -4.29 < 0.0001 [-1.3305; -0.3546]

Quantifying heterogeneity / inconsistency:
tau^2 = 0.0194; tau = 0.1392; I^2 = 50.1% [27.4%; 65.7%]

Tests of heterogeneity (within designs) and inconsistency (between designs):
                    Q d.f. p-value
Total           74.17   37  0.0003
Within designs  49.08   26  0.0040
Between designs 25.10   11  0.0088
[1] "A total of 12 treatments are included in the network."
[1] "A total of 42 studies are included in this analysis."
[1] "A total of 11751 participants are included in this analysis."
[1] "The following studies were included in this analysis: 2 3 4 5 12 15 20 21 25 32 39 43 44 45 46 47 58 59 62 68 71 72 74 75 77 81 103 105 114 119 120 121 123 127 132 135 137 144 149 156 159 160"
[1] "Estimated heterogeneity tau-squared0.02"
[1] "Global test for inconsistency, p-value 0.00882 (Q=25, d.o.f. 11)"
[1] "File created on 2022-01-31"
